Limits...
Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hügl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A, VENTURE-AF Investigato - Eur. Heart J. (2015)

Bottom Line: All events occurred in the VKA arm and all after CA.The number of any adjudicated events (26 vs. 25), any bleeding events (21 vs. 18), and any other procedure-attributable events (5 vs. 5) were similar.In patients undergoing CA for AF, the use of uninterrupted oral rivaroxaban was feasible and event rates were similar to those for uninterrupted VKA therapy.

View Article: PubMed Central - PubMed

Affiliation: Arrhythmia and Electrophysiology Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy Gavazzeni Hospital, Second Arrhythmia and EP Unit, Bergamo, Italy.

No MeSH data available.


Related in: MedlinePlus

Patient disposition during the study.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508487&req=5

EHV177F1: Patient disposition during the study.

Mentions: A total of 291 adult patients with paroxysmal, persistent, or long-standing persistent NVAF scheduled for elective CA at 46 sites opened for enrollment in five countries (Belgium, France, Germany, the UK, and the USA) were screened between February 2013 and September 2014. Of them, 248 were randomized at 37 sites (ITT population; mean of 6 patients per site), 244 received at least one dose of the assigned study drug (safety population), 221 also underwent CA (per-protocol population), 213 patients completed the study, and no patient was lost to follow-up (Figure 1).Figure 1


Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hügl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A, VENTURE-AF Investigato - Eur. Heart J. (2015)

Patient disposition during the study.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508487&req=5

EHV177F1: Patient disposition during the study.
Mentions: A total of 291 adult patients with paroxysmal, persistent, or long-standing persistent NVAF scheduled for elective CA at 46 sites opened for enrollment in five countries (Belgium, France, Germany, the UK, and the USA) were screened between February 2013 and September 2014. Of them, 248 were randomized at 37 sites (ITT population; mean of 6 patients per site), 244 received at least one dose of the assigned study drug (safety population), 221 also underwent CA (per-protocol population), 213 patients completed the study, and no patient was lost to follow-up (Figure 1).Figure 1

Bottom Line: All events occurred in the VKA arm and all after CA.The number of any adjudicated events (26 vs. 25), any bleeding events (21 vs. 18), and any other procedure-attributable events (5 vs. 5) were similar.In patients undergoing CA for AF, the use of uninterrupted oral rivaroxaban was feasible and event rates were similar to those for uninterrupted VKA therapy.

View Article: PubMed Central - PubMed

Affiliation: Arrhythmia and Electrophysiology Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy Gavazzeni Hospital, Second Arrhythmia and EP Unit, Bergamo, Italy.

No MeSH data available.


Related in: MedlinePlus